• Mashup Score: 0
    A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors by ASTCT Talks - 6 month(s) ago

    In this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers’ primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects, the need for robust prospective data before implementation is emphasized. About Dr. Rebecca Gonzalez Dr. Rebecca Gonzalez (@xnyerin) received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy. She completed her PGY2 Oncology residency at West Virginia Univer

    Source: podcasters.spotify.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Looking for more #HCT and #celltherapy pharmacy content for #NationalPharmacyWeek? Check out this recent episode of ASTCT Talks, "A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors": https://t.co/pMZti2BKfr @xnyerin https://t.co/PgZ1haE7jn

  • Mashup Score: 1
    A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma - 6 month(s) ago

    Chimeric antigen receptor T cell (CAR-T) therapy has been applied in the treatment of B-cell lymphoma; however, CAR-T manufacturing requires virus- or non-virus-based genetic modification, which causes high manufacturing costs and potential safety concerns. Antibody–cell conjugation (ACC) technology, which originated from bio-orthogonal click chemistry, provides an efficient approach for arming immune cells with cancer-targeting antibodies without genetic modification. Here, we applied ACC technology in Vγ9Vδ2 T (γδ2 T) cells to generate a novel off-the-shelf CD20-targeting cell therapy ACE1831 (rituximab-conjugated γδ2 T cells) against relapsed/refractory B-cell lymphoma. ACE1831 exhibited superior cytotoxicity against B-cell lymphoma cells and rituximab-resistant cells compared to γδ2 T cells without rituximab conjugation. The in vivo xenograft study demonstrated that ACE1831 treatment strongly suppressed the aggressive proliferation of B-cell lymphoma and prolonged the survival of t

    Source: www.mdpi.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Rx for the Rx of Relapsed/Refractory B-Cell Lymphoma https://t.co/iHVarmT8Rs #mdpicancers via @Cancers_MDPI #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy

  • Mashup Score: 0
    Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies - 6 month(s) ago

    Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of malignancies, especially hematological tumors, but toxicities have tempered its success. The main impediments to the development of CAR-T cell therapies are the following: cytokine release syndrome (CRS), immune-effector-cell-associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), and on-target/off-tumor toxicity (OTOT). This review summarizes these side effects’ underlying mechanisms and manifestations over time. It provides potential prevention and treatment according to the consensus grading, stressing the significance of establishing strategies that anticipate, reduce, and navigate the beginning of these side effects. It is essential to fully comprehend the mechanisms underlying these toxicities to create efficient treatment and preventive approaches.

    Source: www.mdpi.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies https://t.co/5Rsa1rvzzy #mdpijcm via @JCM_MDPI #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy

  • Mashup Score: 0
    Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review - 6 month(s) ago

    The aim of this paper was to review the available evidence on the efficacy and safety of combined or sequential use of PD-1/PD-L1 immune checkpoint inhibitors (ICI) and CAR-T cell therapies in relapsed/refractory (R/R) haematological malignancies. A systematic literature review was performed until 21 November 2022. Inclusion criteria: cohort studies/clinical trials aimed at evaluating the efficacy and/or safety of the combination of CAR-T cell therapy with PD-1/PD-L1 inhibitors in R/R haematological malignancies, which had reported results. Those focusing only on ICI or CAR-T separately or evaluating the combination in other non-hematological solid tumours were excluded. We used a specific checklist for quality assessment of the studies, and then we extracted data on efficacy or efficiency and safety. A total of 1867 articles were identified, and 9 articles were finally included (early phase studies, with small samples of patients and acceptable quality). The main pathologies were B-ce

    Source: www.mdpi.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      Combined or Sequential Rx with Immune Checkpoint Inhibitors and Car-T Cell Rx for the Rx of Hematological Malignancies https://t.co/KBBWnIXSFI #mdpiijms via @IJMS_MDPI #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy

  • Mashup Score: 0
    Cell and Gene Therapy Insights - 7 month(s) ago

    What’s next for the cell and gene therapy market? In Deloitte’s state of the industry survey, stakeholders from across the ecosystem share insights on their optimism for the year ahead and identify areas for caution.

    Source: www2.deloitte.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DeloitteHealth
      DeloitteHealth

      Over 60% of clinical stage #CellTherapy and #GeneTherapy innovators seek partnerships and over 50% are raising capital for commercialization. Explore the future of #PersonalizedMedicine in our report. https://t.co/ubz8iHh7Pm

  • Mashup Score: 1
    CAR T-cell therapy in autoimmune diseases - 7 month(s) ago

    Despite the tremendous progress in the clinical management of autoimmune diseases, many patients do not respond to the currently used treatments. Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B-cell-depleting monoclonal antibodies, such as rituximab, have poor therapeutic efficacy in autoimmune diseases, mainly due to the persistence of autoreactive B cells in lymphatic organs and inflamed tissues.

    Source: www.thelancet.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      CAR T-cell therapy in autoimmune diseases - The Lancet https://t.co/VaF7FvtwEe #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy @TheLancet

Load More